Skip to main content Skip to main navigation menu Skip to site footer

The The association of Hs-Troponin I with cardiac dysfunction and structural changes in chronic heart failure with reduced ejection fraction patients

  • Luh Oliva Saraswati Suastika ,
  • I Gde Raka Widiana ,
  • I Wayan Wita ,
  • Agung Pranoto ,
  • Ida Bagus Rangga Wibhuti ,
  • Ni Made Ayu Wulan Sari ,
  • Melissa Dharmawan ,
  • Rizky Darmawan ,
  • Bagus Made Indrata Saputra ,


Abstract

Introduction: Cardiomyocyte death is the key pathological feature of heart failure with reduced ejection fraction (HFrEF). One of the circulating markers which represent myocardial cell death is cardiac troponin. High sensitivity-troponin I (hs-TnI) has been validated as an acute coronary syndrome diagnostic criteria. But its value and role in chronic heart failure, specifically HFrEF, has been variable in different studies. The aim of this study was to determine whether hs-TnI, an indicator of cardiomyocyte injury, is associated with functional and structural changes in HFrEF patients.

Methods: A hospital-based cross-sectional analytic study was conducted on 72 patients with stable chronic HFrEF between April and October 2022. All subjects underwent echocardiography (Philips EPIQ7 and Affinity 70) and hs-troponin I serum measurement (Abbott Architect assay). Spearman’s test was used to evaluate the correlation between hs-troponin I and left ventricular ejection fraction (LVEF), E/A ratio, left ventricular end-diastolic volume (LVEDV), tricuspid annular plane systolic excursion (TAPSE) and left atrial volume index (LAVI).

Results: hs-TnI concentrations were quantifiable in all samples ranging from 10 to 280.9 pg/mL. hs-TnI was associated significantly with LVEF (r=-0.39; p<0.01), E/A ratio (r=0.328, p=0.01), and LVEDV (r=0.278, p=0.04). hs-TnI was not correlated with TAPSE and LAVI (r=0.241; p=0.07 and r=-0.13; p=0.429, respectively). The correlation between hs-troponin I with LVEF, E/A ratio and LVEDV proved that the degree of myocardial injury is directly associated with left ventricle (LV) systolic and diastolic dysfunction and also with LV dilatation. While it is not correlated with right ventricle (RV) systolic function. Hs-TnI may represent the injury in LV better than RV.

Conclusion: These findings support the association of hs-TnI as a circulating marker of cardiomyocyte injury with LV dysfunction (systolic and diastolic) and dilatation in chronic HFrEF patients. This has expanded the role of hs-TnI in chronic heart disease.

Keywords: diastolic dysfunction hs-troponin heart failure systolic dysfunction

References

  1. Institute for Health Metrics and Evaluation. 2022. Cited: 2nd November 2022. Available from: www.healthdata.org.
  2. Kemenkes. Riset Kesehatan Dasar. 2013. Jakarta, Indonesia: Badan Penelitian Dan Pengembangan Kesehatan.
  3. Tiller D, Russ M, Greiser KH, Nuding S, Ebelt H, Kluttig A, et al. Prevalence of symptomatic heart failure with reduced and with normal ejection fraction in an elderly general population-the CARLA study. PloS one. 2013;8(3):e59225.
  4. Albakri A. Heart failure with reduced ejection fraction: A review of clinical status and meta-analyses of diagnosis by 3D echocardiography and natriuretic peptides-guided heart failure therapy. Trends in Research. 2018;1(4):1–2.
  5. Simmonds SJ, Cuijpers I, Heymans S, Jones EA. Cellular and Molecular Differences between HFpEF and HFrEF: A Step Ahead in an Improved Pathological Understanding. Cells. 2020;9(1):242.
  6. Chen Y, Hua Y, Li X, Arslan IM, Zhang W, Meng G. Distinct types of cell death and the implication in diabetic cardiomyopathy. Frontiers in Pharmacology. 2020;11:42.
  7. Mishra PK, Adameova A, Hill JA, Baines CP, Kang P, Downey M, et al. Guidelines for evaluating myocardial cell death. American Journal of Physiology - Heart and Circulatory Physiology. 2019;317(5):H891–H922.
  8. Katrukha IA, Katrukha AG. Myocardial Injury and the Release of Troponins I and T in the Blood of Patients. Clinical Chemistry. 2020;67(1):124–130.
  9. Hong J, Chatila KF, John JJ, Thakker RA and Kassem H. Insight on the Etiologies of Chronically Elevated Troponin. Current Problems in Cardiology. 2022;00:101204.
  10. Lang RM, Badano LP, Mor-Avi V, Afilalo J, Armstrong A, Ernande L, et al. Recommendations for Cardiac Chamber Quantification by Echocardiography in Adults: An Update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Journal of the American Society of Echocardiography. 2015;16(3):233-271.
  11. Mair J, Lindahl B, Hammarsten O, Muller C, Giannitsis E, Huber K, et al. How is cardiac troponin released from injured myocardium? European Heart Journal: Acute Cardiovascular Care. 2018;7(6): 553–560.
  12. Pascual-Figal DA, Manzano-Fernandez S, Pastor F, Garrido IP, Casas T, Mas JS, et al. Troponin-T monitoring in outpatients with non-ischemic heart failure. Revista Espanola de Cardiologia. 2008;61(7):678–686.
  13. Ahmed KU, Bilkis MR, Islam AKM. Correlation of Cardiac Troponin I with Left Ventricular Systolic Function in Patients with Acute ST-segment Elevated Myocardial Infarction. Faridpur Medical College Journal. 2021;16(1):34-38.
  14. Aimo A, Januzzi JL, Vergaro G, Ripoli A, Latini R, Masson S, et al. Prognostic Value of High-Sensitivity Troponin T in Chronic Heart Failure. Circulation. 2018;137(3):286–297.
  15. Santhanakrishnan R, Chong JPC, Ng TP, Ling LH, Sim D, Toh G. Leong K, et al. Growth differentiation factor 15, ST2, high-sensitivity troponin T, and N-terminal pro brain natriuretic peptide in heart failure with preserved vs. reduced ejection fraction. European journal of heart failure. 2012;14(12):1338–1347.
  16. Suzuki S, Motoki H, Minamisawa M, Okuma Y, Shoin W, Okano T, et al. Prognostic significance of high-sensitivity cardiac troponin in patients with heart failure with preserved ejection fraction. Heart and Vessels. 2019; 34(10):1650–1656.
  17. Yan I, Börschel CS, Neumann JT, Sprunker NA, Makarova N, Kontto J, et al. High-Sensitivity Cardiac Troponin I Levels and Prediction of Heart Failure: Results From the BiomarCaRE Consortium. JACC: Heart Failure. 2020;8(5): 401–411.
  18. Obokata M, Reddy YNV, Melenovsky V, Kane GC, Olson TP, Jarolim P, et al. Myocardial injury and cardiac reserve in patients with heart failure and preserved ejection fraction. Journal of American College of Cardiology. 2018;72(1):29-40.
  19. Otsuka H, Sakuragi S, Yamada K, Tanimoto M, Fujiwara T, Miki T, et al. High Sensitivity Cardiac Troponin T Reflects Presence of Left Ventricular Hypertrophy and Diastolic Dysfunction and Predicts Incidence of Cardiac Events. Journal of Cardiac Failure. 2019;19(10):S166.
  20. Myhre PL, Claggett B, Ballantyne CM, Selvin E, Rosjo H, Omland T, et al. Association Between Circulating Troponin Concentrations, Left Ventricular Systolic and Diastolic Functions, and Incident Heart Failure in Older Adults. JAMA Cardiology. 2019;1:4(10):997-1006.
  21. Albakri A. Heart failure with reduced ejection fraction: A review of clinical status and meta-analyses of diagnosis by 3D echocardiography and natriuretic peptides-guided heart failure therapy. Trends in Research. 2018;1(4):1-2.
  22. Rozenbaum Z, Arbel Y, Granot Y, Cohen D, Shmilovich H, Ziv-Baran T, et al. An association between volumes of the cardiac chambers and troponin levels in individuals submitted to cardiac coronary computed tomography. Clinical Cardiology. 2017;40:879– 885.
  23. Tedjamulia V, Wibhuti IBR, Iswari IS, Nadha KB. Evaluating Low Values of Early Diastolic Velocity (e’) as a Predictor of Major Cardiovascular Events in Patients with Acute Myocardial Infarction. Bali Medical Journal. 2022;11(1):418–424.
  24. Amorim S, Dias P, Rodrigues RA, Araújo V, Macedo F, Maciel MJ, et al. Troponin I as a marker of right ventricular dysfunction and severity of pulmonary embolism. Rev Port Cardiol. 2006 Feb;25(2):181-186.
  25. Dewi MMW, Mulyantari NK, Lestari AAW, Prabawa IPY. The relationship of Soluble Suppression of Tumorigenicity 2 (sST2) and Troponin T (TnT) levels in Acute Myocardial Infarction (AMI) patients at Sanglah General Hospital, Bali, Indonesia. Indonesia Journal of Biomedical Science. 2021;15(2):87–91.
  26. Keller K, Beule J, Schulz A, Coldewey M, Dippold W, Balzer JO. Cardiac troponin I for predicting right ventricular dysfunction and intermediate risk in patients with normotensive pulmonary embolism. Netherland Heart Journal. 2015;23(1):55-61.
  27. Ghidini S, Gasperetti A, Winterton D, Vicenzi M, Busana M, Pedrazzini G, et al. Echocardiographic assessment of the right ventricle in COVID-19: a systematic review. International Journal of Cardiovascular Imaging. 2021;37(12):3499-3512.

How to Cite

Suastika, L. O. S., Widiana, I. G. R., Wita, I. W., Pranoto, A., Wibhuti, I. B. R., Sari, N. M. A. W., Dharmawan, M., Darmawan, R., & Saputra, B. M. I. (2023). The The association of Hs-Troponin I with cardiac dysfunction and structural changes in chronic heart failure with reduced ejection fraction patients. Bali Medical Journal, 12(1), 636–640. https://doi.org/10.15562/bmj.v12i1.3999
ACM ACS APA ABNT Chicago Harvard IEEE MLA Turabian Vancouver
Download Citation
Endnote/Zotero/Mendeley (RIS) BibTeX

HTML
4

Total
0

Share

Search Panel

Luh Oliva Saraswati Suastika
Google Scholar
Pubmed
BMJ Journal

I Gde Raka Widiana
Google Scholar
Pubmed
BMJ Journal

I Wayan Wita
Google Scholar
Pubmed
BMJ Journal

Agung Pranoto
Google Scholar
Pubmed
BMJ Journal

Ida Bagus Rangga Wibhuti
Google Scholar
Pubmed
BMJ Journal

Ni Made Ayu Wulan Sari
Google Scholar
Pubmed
BMJ Journal

Melissa Dharmawan
Google Scholar
Pubmed
BMJ Journal

Rizky Darmawan
Google Scholar
Pubmed
BMJ Journal

Bagus Made Indrata Saputra
Google Scholar
Pubmed
BMJ Journal